AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$ABX

McCauley William Hugh JR sold $1.1M of ABX

McCauley William Hugh JR (COO and CFO) sold 125,000 shares of Abacus Global Management, Inc. (ABX) at $9.10 ($1.14M total) on 2026-08-20.

Original reporting
SEC EDGAR · McCauley William Hugh JR
Published Aug 21, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ABX
Bearish
medium confidence
Mentioned
$ABX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABXBearishLow
01

Why it matters

The insider sale is the first public disclosure of this transaction, offering new data for traders.

02

Market read

New insider sale data may influence short‑term trading decisions for ABX.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs not disclosed.

Relevance 6/10Novelty 5/10Timing: post‑market 2026‑08‑20

Background

Form 4 filing reports insider transactions required by SEC; provides transparent ownership changes.

Company-level read

Ticker impact

$ABXBearishMedium confidence
Context

COO/CFO sold 125,000 shares for $1.137M, reducing his stake to 915,260 shares.

Expected impact

Possible modest downside of 1-2% in the near term.

Evidence & confidence

Sale size is material for a micro‑cap but not large enough to trigger a major move; market may price in slight sell pressure.

Market effects

Sector

Minimal impact on the broader asset‑management sector.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily signal negative outlook.

Key entities

  • Company
    Abacus Global Management, Inc.

    Issuer of the stock (ticker ABX).

  • Individual
    William Hugh McCauley Jr.

    COO and CFO of ABX, reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABX insider trading history →

Related articles

AUG 28
$ABXMed

Abacus Global Management affirms FY26 EPS guidance above estimates

Abacus Global Management (NYSE: ABX) reaffirmed its FY26 adjusted EPS guidance of $1.00 to $1.05, exceeding the analyst estimate of $0.99. The company will report Q2 2026 results on August 6, 2026, with a conference call scheduled for the same day. Abacus specializes in alternative asset management and data-driven financial solutions.

scanx.trade2 min
AUG 24
$ABXHigh

Abacus Q2 Revenue Rises 30%, Adjusted Net Income Beats Guidance – Minichart

Abacus Global Management (NYSE: ABX) reported Q2 2026 revenue of $73.0M, up 30% YoY. Adjusted net income exceeded guidance at $27.1M. Adjusted EBITDA rose 27% to $39.9M, maintaining a 55% margin. The company deployed $200M in capital, up 62% YoY, and raised its quarterly target to $150M-$175M. It also changed its valuation methodology to a market-based approach. Asset management raised over $1B in the last year, with annualized distributions reaching 10%.

minichart.com.sg2 min
AUG 17
$ABXMed

Daily Special: Dimerix, Astral Resources, Midas Minerals, ABx Group, OncoSil Medical

Australian shares fell at midday, with the S&P/ASX 200 down 0.28% to 9,089.40. Sector weakness was led by consumer discretionary, while banks and tech also declined. In small caps, Dimerix gained full US IND control for DMX-652, Astral expanded Theia Deeps drilling, Midas extended Spaatzu copper-silver results, ABx advanced Sunrise approvals, and OncoSil received US FDA approval.

finnewsnetwork.com.au7 min